ALKS Alkermes plc
Healthcare$36.80-0.41%ClosedMarket Cap: $6.13B
As of 2026-05-25
Valuation
P/E (TTM)
23.00
PEG
—
P/B
3.49
P/S
3.93
EV/EBITDA
26.64
DCF Value
$41.59
FCF Yield
3.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.6%
Operating Margin
12.3%
Net Margin
9.8%
ROE
8.8%
ROA
3.6%
ROIC
3.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $392.9M | 84.3% | $-48.3M | $-66.5M | $— | — |
| Q4 null | $384.5M | 88.0% | $58.1M | $49.3M | $— | — |
| FY null | $1.48B | 86.7% | $254.0M | $241.7M | $— | — |
| Q3 null | $394.2M | 86.9% | $89.1M | $82.8M | $— | — |
| Q2 null | $390.7M | 87.3% | $93.0M | $87.1M | $— | — |
| Q1 null | $306.5M | 83.9% | $13.8M | $22.5M | $— | — |
| Q4 null | $430.0M | 85.6% | $162.7M | $146.5M | $— | — |
| FY null | $1.56B | 84.2% | $420.6M | $367.1M | $— | — |
| Q3 null | $378.1M | 83.3% | $104.8M | $92.4M | $— | — |
| Q2 null | $399.1M | 84.6% | $109.9M | $91.4M | $— | — |
| Q1 null | $350.4M | 83.3% | $43.3M | $36.8M | $— | — |
| Q4 2023 | $377.5M | 81.4% | $178.6M | $112.8M | $0.66 | — |